Floatz logo

3vm1001

Osteoarthritis of Knee

CDA Research Group, Inc.Phase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

31 Active assets in the Osteoarthritis of Knee cohort.

Asset / SponsorPhaseRating
Duloxetine
Orthopaedic Arthroscopy Knee and Shoulder Clinic
Phase 4BBB
Naproxen
Pfizer
Phase 3BB
Triamcinalone
Mayo Clinic
Phase 4BB
Remimazolam
Seoul National University Hospital
Phase 4BB
Bxcl501
Poznan University of Medical Sciences
Phase 4BB

View all 50 →

Same molecule, other indications

3vm1001 is also rated in:

osteoarthritisDormant
NR
Indicative ·
/ 100
View asset →
postherpetic neuralgiaDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →